
Pharnext SA’s PXT3003 treatment for patients with Charcot-Marie-Tooth Disease (CMT) has shown positive interim results in its ongoing Phase III …
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics

